New Oral Drug Approved for Herpes Lesions in Immunocompromised Patients
The FDA approved an oral drug for treating herpes lesions in immunocompromised patients who have not responded to other treatments. The drug is part of a new class of medications targeting herpes simplex virus.
Immunocompromised patients with drug-resistant herpes infections may benefit; evidence comes from regulatory approval.
- journal
- MedPage Today
Taken from the source as published — check the details before acting on them.
Target population
The treatment is intended for immunocompromised individuals with mucocutaneous lesions caused by herpes simplex virus.
Common questions
Who is eligible for this new treatment?
Immunocompromised patients with mucocutaneous herpes lesions who have not responded to other treatments.
What is the drug's mechanism of action?
The drug targets the herpes simplex virus by inhibiting a key enzyme involved in viral replication.
Sources
- New Oral Drug Approved for Herpes Lesions MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
